WINTON GROUP Ltd Takes $739,000 Position in Xeris Biopharma Holdings, Inc. $XERS

WINTON GROUP Ltd bought a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 90,793 shares of the company’s stock, valued at approximately $739,000. WINTON GROUP Ltd owned 0.05% of Xeris Biopharma as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of XERS. Geode Capital Management LLC lifted its position in Xeris Biopharma by 7.2% in the second quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company’s stock worth $17,052,000 after buying an additional 244,862 shares during the last quarter. Qube Research & Technologies Ltd increased its position in Xeris Biopharma by 67.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock valued at $14,429,000 after acquiring an additional 1,245,188 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the period. Millennium Management LLC raised its stake in shares of Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after acquiring an additional 369,420 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Xeris Biopharma by 27.8% in the 2nd quarter. Legal & General Group Plc now owns 1,804,203 shares of the company’s stock worth $8,426,000 after acquiring an additional 392,589 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Trading Up 0.8%

Shares of XERS traded up $0.05 during trading hours on Friday, reaching $5.53. 285,561 shares of the company traded hands, compared to its average volume of 2,048,657. The stock’s fifty day moving average price is $6.94 and its 200 day moving average price is $7.53. The company has a current ratio of 2.19, a quick ratio of 1.57 and a debt-to-equity ratio of 16.10. The firm has a market cap of $952.68 million, a price-to-earnings ratio of -553.05 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a 12-month low of $3.81 and a 12-month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings results on Monday, March 2nd. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. The company had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. Sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current year.

Wall Street Analyst Weigh In

XERS has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings raised shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a research report on Monday, March 2nd. Finally, Barclays began coverage on Xeris Biopharma in a research note on Monday, December 8th. They set an “overweight” rating and a $9.00 target price on the stock. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.80.

Insider Activity at Xeris Biopharma

In other news, insider John Patrick Shannon, Jr. sold 24,907 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $7.08, for a total transaction of $176,341.56. Following the transaction, the insider directly owned 2,705,346 shares of the company’s stock, valued at approximately $19,153,849.68. This trade represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $8.00, for a total transaction of $120,000.00. Following the sale, the insider directly owned 1,685,426 shares of the company’s stock, valued at $13,483,408. This represents a 0.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 225,308 shares of company stock valued at $1,626,103 over the last 90 days. 6.47% of the stock is currently owned by insiders.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.